科学｜自宅で注射できる認知症薬承認 / Science | Approval of a dementia drug that can be self-injected at home

Summary

On September 16, 2023, the Ministry of Health, Labour and Welfare approved the subcutaneous injection treatment for Alzheimer’s disease, known as “lecanemab.”

This new medication is designed to allow patients to self-administer injections at home, in addition to the traditional intravenous therapy, which is expected to reduce the burden on patients and their families. The latest information on Alzheimer’s treatment is also being provided, highlighting the expansion of treatment options.

Dialogue

This dialogue is fictional and based on the article.

Chako: Hey Log, did you hear that there’s a new Alzheimer’s medication that you can inject at home?

Log: Yeah, it’s the drug “Lecanemab” that Eisai has approved, right? Being able to self-inject is a huge benefit for patients, I think.

Chako: But isn’t getting an injection scary? It sounds painful, and I wonder if I could do it properly.

Log: It’s true that there might be some anxiety about injections, but thanks to advancements in medicine, self-management is becoming more feasible. Navi, what do you think?

Navi: This medication aims to reduce the burden on patients, and being able to receive treatment at home increases the chances of a more comfortable life. Just to add.

Admin’s Note

I felt that the approval of this new dementia treatment could bring great hope to patients and their families. With the possibility of self-injection at home, the burden of regular hospital visits will be reduced, allowing for a more independent lifestyle. However, it is important to gather more information about its effectiveness and safety. While it’s encouraging that patients will have more options, it’s equally crucial to approach this information carefully. I was particularly struck by how Chako expressed her concerns about the injections during our conversation.